

DBCO-PEG4-Val-Cit-PAB-MMAF biochemical

DBCO-PEG4-Val-Cit-PAB-MMAF

CATALOG #
AAA228247


PRODUCT SYNONYMS

DBCO-PEG4-Val-Cit-PAB-MMAF; DBCO-PEG4-Val-Cit-PAB-MMAF biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2244602-23-9
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Tenofovir-C3-O-C15-CF3 ammonium, CAS 2611373-80-7



Structure
Tenofovir-C3-O-C15-CF3 ammonium, CAS 2611373-80-7

ADDITIONAL INFORMATION

Related Product Information for DBCO-PEG4-Val-Cit-PAB-MMAF biochemical	DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).
References	1. Pribut N, et al. omega-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. J Med Chem. 2021 Sep 9;64(17):12917-12937.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.